Ask
Search
My library
ORKG

ORKG Ask

Our mission is to organize scholarly knowledge and make it accessible to humans and machines.

About

About ORKG Ask
Report issue
Statistics
Contact

Legal

Terms of use
Data protection (sheet)
Imprint
Accessibility
License

Technical

We
open source
System status
Changelog
Frontend: v1.41.0
Backend: v1.13.4

We use cookies to provide a better user experience.

Data Protection

Population Pharmacokinetic Study of Teicoplanin in

O Petitjean
O Lortholary
M Tod
N Rizzo
C Padoin
O Biard
P Casassus

Publication date

January 1995

Abstract

teicoplanin in severely neutropenic patients. Population pharmacokinetic study o

Extracted data

Related items

Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study

January 2014

The aims of this study were to describe the variability in protein binding of teicoplanin in critica...

Population pharmacokinetics of teicoplanin in preterm and term neonates: Is it time for a new dosing regimen?

Kontou, A. Sarafidis, K. Begou, O. Gika, H.G. Tsiligiannis, A. Ogungbenro, K. Dokoumetzidis, A. Agakidou, E. Roilides, E.

January 2020

Our objective was to develop a population pharmacokinetic (PK) model in order to evaluate the curren...

Pharmacokinetics of teicoplanin

S. Ripa
L. Ferrante
F. Mignini
E. Falcioni

January 1988

We investigated the pharmacokinetic properties of teicoplanin, after 200 mg i.v. and i.m. administra...

Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy

Byrne, C. J.
Roberts, J. A.
McWhinney, B.
Ryder, S. A.
Fennell, J. P.
O'Byrne, P.
Deasy, E.
Egan, S.
Desmond, R.
Enright, H.
D'Arcy, D. M.
McHugh, J.

March 2017

Objectives: To describe the population pharmacokinetics of teicoplanin in adult patients with haemat...

Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen

Cazaubon, Yoann
Venisse, Nicolas
Mimoz, Olivier
Maire, Pascal
Ducher, Michel
Bourguignon, Laurent
Goutelle, Sylvain

October 2017

International audienceObjectives: To investigate the population pharmacokinetics of teicoplanin in p...

Population pharmacokinetics of teicoplanin in children.

Ramos-Martín, V
Paulus, S
Siner, S
Scott, E
Padmore, K
Newland, P
Drew, R J
Felton, T W
Docobo-Pérez, F
Pizer, B
Pea, F
Peak, M
Turner, M A
Beresford, M W
Hope, W W

November 2014

Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't. This trial has been registered in...

Population Pharmacokinetics of Unbound and Total Teicoplanin in Critically Ill Pediatric Patients

Aulin, L. B.S.
De Paepe, P.
Dhont, E.
de Jaeger, A.
Vande Walle, J.
Vandenberghe, W.
McWhinney, B. C.
Ungerer, J. P.J.
van Hasselt, J. G.C.
De Cock, P. A.J.G.

January 2020

Background and Objectives: Teicoplanin is a highly protein-bound antibiotic, increasingly used to tr...

Population pharmacokinetics of unbound and total teicoplanin in critically ill pediatric patients

Aulin, L. B. S.
De Paepe, Peter
Dhont, Evelyn
de Jaeger, Annik
Vande Walle, Johan
Vandenberghe, Wim
McWhinney, B. C.
Ungerer, J. P. J.
van Hasselt, J. G. C.
De Cock, Pieter

January 2021

Background and Objectives Teicoplanin is a highly protein-bound antibiotic, increasingly used to tre...

Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy.

Ramos-Martín, V
Neely, MN
McGowan, P
Siner, S
Padmore, K
Peak, M
Beresford, MW
Turner, MA
Paulus, S
Hope, WW

November 2016

There is uncertainty about the optimal teicoplanin regimens for neonates. The study aim was to deter...

Population pharmacokinetics of teicoplanin in children

Ramos-Mart\uedn, V.
Paulus, S.
Siner, S.
Scott, E.
Padmore, K.
Newland, P.
Drew, R. J.
Felton, T. W.
Docobo-P\ue9rez, F.
Pizer, B.
Pea, F.
Peak, M.
Turner, M. A.
Beresford, M. W.
Hope, W. W.

January 2014

Teicoplanin is frequently administered to treat Gram-positive infections in pediatric patients. Howe...

Teicoplanin in patients with acute leukaemia and febrile neutropenia: A special population benefiting from higher dosages

Pea F.
Viale P.
Candoni A.
Pavan F.
Pagani L.
Damiani D.
Casini M.
Furlanut M.

January 2004

Objective: To define the optimal dosage regimen of teicoplanin that ensures early therapeutically re...

Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study

Roberts, JA
Stove, V
De Waele, JJ
Sipinkoski, B
McWhinney, B
Ungerer, JPJ
Akova, M
Bassetti, M
Dimopoulos, G
Kaukonen, K-M
Koulenti, D
Martin, C
Montravers, P
Rello, J
Rhodes, A
Starr, T
Wallis, SC
Lipman, J
DALI Study Authors

May 2014

The aims of this study were to describe the variability in protein binding of teicoplanin in critica...

Variability In Protein Binding Of Teicoplanin And Achievement Of Therapeutic Drug Monitoring Targets In Critically Ill Patients: Lessons From The Dali Study

Roberts, J. A.
Stove, V.
De Waele, J. J.
Sipinkoski, B.
McWhinney, B.
Ungerer, J. P. J.
Akova, M.
Bassetti, M.
Dimopoulos, G.
Kaukonen, K. -M.
Koulenti, D.
Martin, C.
Montravers, P.
Rellom, J.
Rhodes, A.
Starr, T.
Wallis, S. C.
Lipman, J.

January 2014

The aims of this study were to describe the variability in protein binding of teicoplanin in critica...

Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study

January 2014

The aims of this study were to describe the variability in protein binding of teicoplanin in critica...

Population pharmacokinetics of teicoplanin in preterm and term neonates: Is it time for a new dosing regimen?

Kontou, A. Sarafidis, K. Begou, O. Gika, H.G. Tsiligiannis, A. Ogungbenro, K. Dokoumetzidis, A. Agakidou, E. Roilides, E.

January 2020

Our objective was to develop a population pharmacokinetic (PK) model in order to evaluate the curren...

Pharmacokinetics of teicoplanin

S. Ripa
L. Ferrante
F. Mignini
E. Falcioni

January 1988

We investigated the pharmacokinetic properties of teicoplanin, after 200 mg i.v. and i.m. administra...

Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy

Byrne, C. J.
Roberts, J. A.
McWhinney, B.
Ryder, S. A.
Fennell, J. P.
O'Byrne, P.
Deasy, E.
Egan, S.
Desmond, R.
Enright, H.
D'Arcy, D. M.
McHugh, J.

March 2017

Objectives: To describe the population pharmacokinetics of teicoplanin in adult patients with haemat...

Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen

Cazaubon, Yoann
Venisse, Nicolas
Mimoz, Olivier
Maire, Pascal
Ducher, Michel
Bourguignon, Laurent
Goutelle, Sylvain

October 2017

International audienceObjectives: To investigate the population pharmacokinetics of teicoplanin in p...

Population pharmacokinetics of teicoplanin in children.

Ramos-Martín, V
Paulus, S
Siner, S
Scott, E
Padmore, K
Newland, P
Drew, R J
Felton, T W
Docobo-Pérez, F
Pizer, B
Pea, F
Peak, M
Turner, M A
Beresford, M W
Hope, W W

November 2014

Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't. This trial has been registered in...

Population Pharmacokinetics of Unbound and Total Teicoplanin in Critically Ill Pediatric Patients

Aulin, L. B.S.
De Paepe, P.
Dhont, E.
de Jaeger, A.
Vande Walle, J.
Vandenberghe, W.
McWhinney, B. C.
Ungerer, J. P.J.
van Hasselt, J. G.C.
De Cock, P. A.J.G.

January 2020

Background and Objectives: Teicoplanin is a highly protein-bound antibiotic, increasingly used to tr...

Population pharmacokinetics of unbound and total teicoplanin in critically ill pediatric patients

Aulin, L. B. S.
De Paepe, Peter
Dhont, Evelyn
de Jaeger, Annik
Vande Walle, Johan
Vandenberghe, Wim
McWhinney, B. C.
Ungerer, J. P. J.
van Hasselt, J. G. C.
De Cock, Pieter

January 2021

Background and Objectives Teicoplanin is a highly protein-bound antibiotic, increasingly used to tre...

Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy.

Ramos-Martín, V
Neely, MN
McGowan, P
Siner, S
Padmore, K
Peak, M
Beresford, MW
Turner, MA
Paulus, S
Hope, WW

November 2016

There is uncertainty about the optimal teicoplanin regimens for neonates. The study aim was to deter...

Population pharmacokinetics of teicoplanin in children

Ramos-Mart\uedn, V.
Paulus, S.
Siner, S.
Scott, E.
Padmore, K.
Newland, P.
Drew, R. J.
Felton, T. W.
Docobo-P\ue9rez, F.
Pizer, B.
Pea, F.
Peak, M.
Turner, M. A.
Beresford, M. W.
Hope, W. W.

January 2014

Teicoplanin is frequently administered to treat Gram-positive infections in pediatric patients. Howe...

Teicoplanin in patients with acute leukaemia and febrile neutropenia: A special population benefiting from higher dosages

Pea F.
Viale P.
Candoni A.
Pavan F.
Pagani L.
Damiani D.
Casini M.
Furlanut M.

January 2004

Objective: To define the optimal dosage regimen of teicoplanin that ensures early therapeutically re...

Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study

Roberts, JA
Stove, V
De Waele, JJ
Sipinkoski, B
McWhinney, B
Ungerer, JPJ
Akova, M
Bassetti, M
Dimopoulos, G
Kaukonen, K-M
Koulenti, D
Martin, C
Montravers, P
Rello, J
Rhodes, A
Starr, T
Wallis, SC
Lipman, J
DALI Study Authors

May 2014

The aims of this study were to describe the variability in protein binding of teicoplanin in critica...

Variability In Protein Binding Of Teicoplanin And Achievement Of Therapeutic Drug Monitoring Targets In Critically Ill Patients: Lessons From The Dali Study

Roberts, J. A.
Stove, V.
De Waele, J. J.
Sipinkoski, B.
McWhinney, B.
Ungerer, J. P. J.
Akova, M.
Bassetti, M.
Dimopoulos, G.
Kaukonen, K. -M.
Koulenti, D.
Martin, C.
Montravers, P.
Rellom, J.
Rhodes, A.
Starr, T.
Wallis, S. C.
Lipman, J.

January 2014

The aims of this study were to describe the variability in protein binding of teicoplanin in critica...

Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study

January 2014

The aims of this study were to describe the variability in protein binding of teicoplanin in critica...

Population pharmacokinetics of teicoplanin in preterm and term neonates: Is it time for a new dosing regimen?

Kontou, A. Sarafidis, K. Begou, O. Gika, H.G. Tsiligiannis, A. Ogungbenro, K. Dokoumetzidis, A. Agakidou, E. Roilides, E.

January 2020

Our objective was to develop a population pharmacokinetic (PK) model in order to evaluate the curren...

Pharmacokinetics of teicoplanin

S. Ripa
L. Ferrante
F. Mignini
E. Falcioni

January 1988

We investigated the pharmacokinetic properties of teicoplanin, after 200 mg i.v. and i.m. administra...